<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cutaneous manifestations of internal malignancy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cutaneous manifestations of internal malignancy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cutaneous manifestations of internal malignancy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Cindy Owen, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey Callen, MD, FACP, FAAD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The cutaneous manifestations of internal malignancy include a wide variety of nonmalignant skin disorders that occur in association with malignancy (paraneoplastic dermatoses) and skin disorders that represent infiltration of malignant cells into the skin due to metastatic or locoregional spread of disease or the deposition of circulating tumor cells (eg, leukemia cutis) [<a href="#rid1">1,2</a>]. When paraneoplastic dermatoses develop before an internal neoplasm is diagnosed, recognition of these disorders can aid in the diagnosis of the malignancy.</p><p class="headingAnchor" id="H28413835"><span class="h1">PARANEOPLASTIC DERMATOSES</span><span class="headingEndMark"> — </span>Paraneoplastic dermatoses are a group of skin disorders that have strong associations with internal malignancies. Curth's postulates can aid in the classification of dermatoses as paraneoplastic  (<a class="graphic graphic_table graphicRef71642" href="/z/d/graphic/71642.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. Cutaneous findings resulting from the entry of tumor cells into the skin are not considered paraneoplastic dermatoses. (See <a class="local">'Non-paraneoplastic cutaneous manifestations of internal malignancy'</a> below.)</p><p>The paraneoplastic dermatoses reviewed below are organized according to common clinical features. Some of these dermatoses may also develop in the absence of malignancy. However, the detection of a potential paraneoplastic dermatosis warrants consideration of the possibility of malignancy.</p><p class="headingAnchor" id="H8"><span class="h2">Hyperkeratotic and proliferative dermatoses</span><span class="headingEndMark"> — </span>Acanthosis nigricans, florid cutaneous papillomatosis, the sign of Leser-Trélat, tripe palm, acquired ichthyosis, palmoplantar keratoderma, and Bazex syndrome are examples of paraneoplastic disorders that present with clinical features of hyperkeratosis or epidermal proliferation.</p><p class="headingAnchor" id="H9"><span class="h3">Acanthosis nigricans</span><span class="headingEndMark"> — </span>Acanthosis nigricans is a reactive skin pattern that typically presents as velvety to verrucous hyperpigmented plaques in intertriginous areas  (<a class="graphic graphic_picture graphicRef94426 graphicRef72964 graphicRef66384 graphicRef81693" href="/z/d/graphic/94426.html" rel="external">picture 1A-D</a>). While the majority of cases of acanthosis nigricans are benign and associated with obesity and insulin resistance, the disease also can herald the onset of malignancy. (See  <a class="medical medical_review" href="/z/d/html/13754.html" rel="external">"Acanthosis nigricans"</a>.)</p><p>Gastric cancers are the most common cause of malignant acanthosis nigricans; other cancers that have been reported in association with this disorder include hepatocellular carcinoma and adenocarcinomas of the lung, ovary, endometrium, kidneys, pancreas, bladder, breast, and other sites [<a href="#rid2">2-9</a>]. In one study of 227 patients with internal malignancy-associated acanthosis nigricans, gastric adenocarcinoma was the underlying malignancy in 55 percent [<a href="#rid10">10</a>]. Most commonly, the skin manifestations accompany the malignancy, but they can precede or follow the diagnosis of cancer. (See  <a class="medical medical_review" href="/z/d/html/2513.html" rel="external">"Clinical features, diagnosis, and staging of gastric cancer"</a>.)</p><p>Compared with patients with obesity or insulin resistance, malignancy-associated acanthosis nigricans typically has a more striking clinical presentation. Patients tend to be older, are generally not obese, and have often experienced recent unintentional weight loss leading to a cachectic appearance. The cutaneous plaques are florid and may develop in unusual locations (eg, oral cavity, palms and soles) or in combination with the sudden appearance of multiple skin tags and eruptive seborrheic keratoses (ie, the sign of Leser-Trélat)  (<a class="graphic graphic_picture graphicRef63422" href="/z/d/graphic/63422.html" rel="external">picture 2</a>) [<a href="#rid11">11-13</a>] (see <a class="local">'Sign of Leser-Trélat'</a> below). In addition, acanthosis nigricans can occur in conjunction with tripe palms (see <a class="local">'Tripe palm'</a> below). (See  <a class="medical medical_review" href="/z/d/html/13754.html" rel="external">"Acanthosis nigricans", section on 'Malignancy-associated acanthosis nigricans'</a>.)</p><p>Suspicion for malignancy should arise when patients present with extensive or rapidly progressive acanthosis nigricans, mucous membrane involvement, prominent sole and palm involvement, or no other identifiable cause of acanthosis nigricans. Malignancy-associated acanthosis nigricans is best treated by definitive treatment of the underlying malignancy, which can lead to resolution of the skin condition [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/z/d/html/13754.html" rel="external">"Acanthosis nigricans", section on 'Diagnosis and patient evaluation'</a>.)</p><p class="headingAnchor" id="H138853380"><span class="h3">Florid cutaneous papillomatosis</span><span class="headingEndMark"> — </span>Florid cutaneous papillomatosis is an obligatory paraneoplastic syndrome characterized by the rapid development of wart-like lesions [<a href="#rid15">15-19</a>]. Lesions often appear first on the dorsal hands but can become widespread and are often pruritic. Clinically, lesions are indistinguishable from human papillomavirus (HPV)-associated verrucae, but histopathology shows no vacuolization of keratinocytes and absence of parakeratosis and viral inclusions.</p><p>Florid cutaneous papillomatosis is associated with underlying cancer of the stomach (in the majority of cases) as well as carcinomas of the breast, bladder, ovary, uterus, prostate, and lung [<a href="#rid17">17-19</a>]. Florid cutaneous papillomatosis may co-occur with the sign of Leser-Trélat and acanthosis nigricans [<a href="#rid17">17</a>]. Florid cutaneous papillomatosis typically occurs before or concurrent with the adenocarcinoma and tends to remit with successful treatment of the neoplasm.</p><p class="headingAnchor" id="H3208461"><span class="h3">Sign of Leser-Trélat</span><span class="headingEndMark"> — </span>The sign of Leser-Trélat, which is classically described as the explosive onset of multiple pruritic seborrheic keratoses, often with an inflammatory base, can be an ominous sign of internal malignancy [<a href="#rid13">13,20-22</a>]. The abrupt development of the seborrheic keratoses (often within three to six months) is characteristic. Acanthosis nigricans is a common associated clinical feature [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/z/d/html/5573.html" rel="external">"Overview of benign lesions of the skin", section on 'Seborrheic keratosis'</a> and <a class="local">'Acanthosis nigricans'</a> above.)</p><p>The sign of Leser-Trélat most often occurs prior to the diagnosis of malignancy but may also be recognized after or concurrently with the malignancy diagnosis [<a href="#rid23">23</a>]. A wide variety of malignancies have been reported to occur in association with the sign of Leser-Trélat [<a href="#rid23">23</a>]. Gastrointestinal adenocarcinoma (eg, stomach, liver, colorectal, or pancreatic adenocarcinoma) is the most common class of associated malignancy. However, lymphoid malignancies (including cutaneous T cell lymphoma), breast cancer, lung cancer, and other cancers can occur in association with the sign of Leser-Trélat [<a href="#rid20">20,24,25</a>]. It is likely that various cytokines and other growth factors produced by the neoplasm are responsible for the abrupt appearance of the seborrheic keratoses. In around 50 percent of patients, the eruption resolves after treatment of the underlying malignancy [<a href="#rid23">23</a>]. </p><p>Of note, there are case reports of eruptions of seborrheic keratoses occurring in association with pregnancy, benign neoplasms, and other disorders, as well as in the absence of an associated disease [<a href="#rid23">23</a>]. Inflammation of existing seborrheic keratoses and new eruptions of inflamed seborrheic keratoses have also occurred during chemotherapy [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H15"><span class="h3">Tripe palm</span><span class="headingEndMark"> — </span>Tripe palm (also known as acanthosis palmaris and acquired pachydermatoglyphia [<a href="#rid26">26</a>]) refers to a characteristic velvety thickening of the palms with a ridged or rugose appearance  (<a class="graphic graphic_picture graphicRef61955" href="/z/d/graphic/61955.html" rel="external">picture 3</a>). The term is derived from its resemblance to the stomach mucosa of ruminants (tripe). Concurrent acanthosis nigricans is often present [<a href="#rid27">27</a>]. </p><p>Tripe palm is predominantly associated with gastric or lung cancer, although it is less frequently described in association with other malignancies or as an idiopathic condition [<a href="#rid26">26-28</a>]. In some cases, tripe palm is the initial presenting feature of the underlying malignancy [<a href="#rid27">27</a>]. In a review of 77 published cases of tripe palm, improvement or resolution of tripe palm occurred in one-third of patients after beginning treatment for malignancy [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H28414251"><span class="h3">Acquired ichthyosis</span><span class="headingEndMark"> — </span>Ichthyosis is a generalized scaling of the skin that can be either congenital or acquired. Acquired ichthyosis can be associated with inflammatory, endocrinologic, and neoplastic processes [<a href="#rid29">29</a>]. The presentation of acquired ichthyosis is similar to the inherited condition ichthyosis vulgaris, with prominent fish-like, relatively large scales adherent to the skin; however, the scaling in acquired disease may also be present on the palms and soles and in skin flexures  (<a class="graphic graphic_picture graphicRef57819 graphicRef64680" href="/z/d/graphic/57819.html" rel="external">picture 4A-B</a>). </p><p>Hodgkin lymphoma is the most common malignancy associated with acquired ichthyosis [<a href="#rid2">2,30,31</a>]. Less frequently reported associations include other CD30<sup>+</sup> lymphoproliferative disorders (eg, anaplastic large cell lymphoma or lymphomatoid papulosis); leiomyosarcoma; multiple myeloma; cutaneous T cell lymphoma; Kaposi's sarcoma; breast, lung, or bladder carcinoma; or other malignancies [<a href="#rid29">29,32</a>]. Isolated cases in the setting of graft versus host disease following allogeneic bone marrow transplantation also have been reported [<a href="#rid33">33</a>]. Postulated mechanisms for the development of acquired ichthyosis include the secretion of keratinocyte growth factors by the tumor [<a href="#rid28">28</a>] or an autoimmune response directed against the skin [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/3549.html" rel="external">"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease"</a> and  <a class="medical medical_review" href="/z/d/html/3548.html" rel="external">"Clinical manifestations and diagnosis of chronic graft-versus-host disease"</a>.)</p><p>In most cases, malignancy-associated acquired ichthyosis is noted after the diagnosis of the underlying malignancy. However, there are a few reports in which recognition of acquired ichthyosis led to the diagnosis of a malignancy [<a href="#rid30">30</a>]. Acquired ichthyosis usually improves with treatment of the malignancy [<a href="#rid34">34</a>]. </p><p class="headingAnchor" id="H28414558"><span class="h3">Palmoplantar keratoderma</span><span class="headingEndMark"> — </span>Palmoplantar keratoderma is a clinical finding characterized by thickening of skin on the palms and soles. The classic form of palmoplantar keratoderma associated with malignancy is Howel-Evans syndrome (OMIM #148500), an autosomal dominant form of palmoplantar keratoderma associated with yellow, wax-like hyperkeratosis on the palms and soles (also referred to as tylosis) and markedly increased risk for squamous cell carcinoma of the esophagus  (<a class="graphic graphic_picture graphicRef74683" href="/z/d/graphic/74683.html" rel="external">picture 5</a>) [<a href="#rid2">2,35</a>]. Tylosis with esophageal cancer is another name for this condition. (See  <a class="medical medical_review" href="/z/d/html/2274.html" rel="external">"Epidemiology and pathobiology of esophageal cancer", section on 'Tylosis'</a>.)</p><p>The keratoderma of Howel-Evans syndrome primarily affects weight-bearing areas on the sole of the foot and may be accompanied by oral leukoplakia. The palmoplantar keratoderma usually becomes evident in childhood and the associated esophageal cancer is usually diagnosed in adulthood. </p><p>Sporadic cases of tylosis have also been associated with Hodgkin lymphoma, leukemia, and breast cancer [<a href="#rid20">20,36</a>]. In addition, palmoplantar keratoderma is a rare presentation of the T cell malignancy mycosis fungoides [<a href="#rid37">37</a>]. Palmoplantar keratoderma can also occur in a wide variety of conditions not associated with malignancy [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/z/d/html/2274.html" rel="external">"Epidemiology and pathobiology of esophageal cancer", section on 'Epidemiology'</a>.)</p><p class="headingAnchor" id="H16"><span class="h3">Bazex syndrome</span><span class="headingEndMark"> — </span>Bazex syndrome (acrokeratosis paraneoplastica) is a rare paraneoplastic phenomenon that is strongly associated with squamous cell carcinoma of the upper aerodigestive tract, but it has also been reported with a number of other tumors [<a href="#rid39">39-44</a>]. In a systematic review of the literature that identified 77 patients with Bazex syndrome, the underlying neoplasms were squamous cell carcinoma of the head and neck in 39 percent and squamous cell carcinoma of the lung in 11 percent, followed by gastrointestinal adenocarcinoma, genitourinary tumors, lymphomas, and lung adenocarcinoma [<a href="#rid45">45</a>]. Patients present with violaceous, psoriasiform plaques predominantly located in acral areas (especially the fingers, toes, nose, and helices)  (<a class="graphic graphic_picture graphicRef66781 graphicRef66625 graphicRef79717" href="/z/d/graphic/66781.html" rel="external">picture 6A-C</a>) [<a href="#rid46">46</a>]. Nail dystrophy, palmoplantar keratoderma, and alopecia are common. </p><p>In most patients, the cutaneous manifestations of Bazex syndrome precede the diagnosis of malignancy [<a href="#rid45">45-47</a>]. In a 1995 review of the literature that identified 109 reported cases of Bazex syndrome preceding malignancy, the average time to the discovery of the malignancy was 12 months (range 1 to 72 months) [<a href="#rid46">46</a>]. Malignancy is diagnosed concurrently or before Bazex syndrome manifestations in approximately one-third of patients [<a href="#rid44">44</a>].</p><p>The lesions of Bazex syndrome are usually resistant to targeted therapies, but treatment of the neoplasm usually leads to resolution of the cutaneous findings [<a href="#rid40">40,47</a>]. However, there are reports of patients for whom the cutaneous manifestations persist following successful tumor therapy [<a href="#rid48">48</a>].</p><p>The best approach to the treatment of patients with incurable malignancy or persistent symptoms is unclear. Treatment with different topical and systemic agents, as well as psoralen plus ultraviolet A (PUVA) phototherapy, has been described in case reports with varying responses. Clinically significant improvement with oral <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> has been described in multiple case reports [<a href="#rid49">49-51</a>].</p><p class="headingAnchor" id="H3208324"><span class="h2">Inflammatory dermatoses</span><span class="headingEndMark"> — </span>Inflammation manifesting as erythematous or violaceous skin eruptions is a primary feature of multiple paraneoplastic dermatoses. Examples include Sweet syndrome, dermatomyositis, erythroderma, erythema gyratum repens, necrolytic migratory erythema, and pancreatic panniculitis.</p><p class="headingAnchor" id="H3208878"><span class="h3">Sweet syndrome</span><span class="headingEndMark"> — </span>Sweet syndrome (acute febrile neutrophilic dermatosis) consists of a cutaneous eruption characterized by a dermal nonvasculitic neutrophilic infiltration, fever, and peripheral neutrophilia [<a href="#rid52">52</a>]. It is associated with an underlying disease in up to 50 percent of patients. Sweet syndrome has a female predominance, except in cases associated with malignancy where no female predominance is noted [<a href="#rid53">53</a>].</p><p>Approximately 20 percent of patients with Sweet syndrome have an underlying malignancy [<a href="#rid54">54</a>]. Histiocytoid Sweet syndrome, a distinct histologic variant of Sweet syndrome, has a higher risk of underlying malignancy (approximately 40 percent of patients) [<a href="#rid55">55</a>]. In a retrospective study of 52 patients with Sweet syndrome, malignancy-associated Sweet syndrome was more likely to present with anemia, leukopenia, and thrombocytopenia than non-malignancy-associated Sweet syndrome [<a href="#rid56">56</a>]. The most common malignancies associated with Sweet syndrome are acute myelogenous leukemia and myelodysplastic syndrome.</p><p>In malignancy-associated Sweet syndrome, hematologic malignancies outnumber solid malignancies by a ratio of 4:1 to 8:1 [<a href="#rid57">57</a>]. Occurrences with solid tumors, lymphomas, and plasma cell dyscrasias also have been reported. Sweet syndrome may precede, follow, or appear concurrently with a diagnosis of malignancy and may be an indicator of malignancy recurrence. Sweet syndrome is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/13784.html" rel="external">"Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p>The cutaneous eruption consists of tender, well-demarcated, erythematous to violaceous papules and plaques with an irregular pseudo-vesiculated surface  (<a class="graphic graphic_picture graphicRef79243 graphicRef74393 graphicRef50526" href="/z/d/graphic/79243.html" rel="external">picture 7A-C</a>). The plaques may have a central yellowish discoloration, creating a targetoid appearance, and pustulation and blistering can occur. The plaques may cause pain and a burning sensation, but usually are not pruritic. Pathergy can occur in Sweet syndrome, with lesions developing at sites of skin injury.</p><p>The papules and plaques of Sweet syndrome are most often found on the face, neck, and upper extremities, especially the dorsum of hands, but can occur anywhere. Oral manifestations are uncommon but may occur in approximately 10 percent of patients with hematologic malignancy-associated Sweet syndrome. Oral lesions present as pseudo-vesicular or pustular initially and later may ulcerate and resemble aphthae [<a href="#rid53">53</a>]. On the lower extremities, Sweet syndrome can resemble erythema nodosum  (<a class="graphic graphic_picture graphicRef63142" href="/z/d/graphic/63142.html" rel="external">picture 8</a>). Fever, leukocytosis, arthralgias, and episcleritis accompany the skin lesions. Infection must be ruled out in all cases.</p><p>The frequency with which malignancy-associated Sweet syndrome resolves with treatment of the malignancy is unknown. The standard and most effective therapy is <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>. However, the disease may recur upon discontinuation of prednisone. (See  <a class="medical medical_review" href="/z/d/html/86567.html" rel="external">"Sweet syndrome (acute febrile neutrophilic dermatosis): Management and prognosis"</a>.)</p><p>VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome, an autoinflammatory disease that may present with findings of Sweet syndrome, has also occurred in association with hematologic malignancy. (See  <a class="medical medical_review" href="/z/d/html/122508.html" rel="external">"Autoinflammatory diseases mediated by NFkB and/or aberrant TNF activity", section on 'Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome'</a>.)</p><p class="headingAnchor" id="H3209272"><span class="h3">Dermatomyositis</span><span class="headingEndMark"> — </span>Dermatomyositis is a condition that presents with numerous cutaneous findings and, in most cases, an associated inflammatory myopathy (clinically amyopathic dermatomyositis is also described and linked with malignancy). The skin findings of dermatomyositis include scaly violaceous papules overlying the bony prominences of the hands (Gottron papules), violaceous patches on the periorbital skin (heliotrope eruption), photodistributed poikilodermatous patches and plaques, scaly plaques on the scalp and lateral thighs, periungual telangiectasia, and ragged cuticles  (<a class="graphic graphic_picture graphicRef63383 graphicRef56879 graphicRef68649 graphicRef54230 graphicRef59545" href="/z/d/graphic/63383.html" rel="external">picture 9A-E</a>). The myopathy usually presents with a progressive, symmetric, proximal weakness. (See  <a class="medical medical_review" href="/z/d/html/5159.html" rel="external">"Clinical manifestations of dermatomyositis and polymyositis in adults"</a>.)</p><p>Adults with dermatomyositis have increased risk for malignancy. In a systematic review and meta-analysis, the following factors were associated with an increased risk of malignancy: older age, male sex, cutaneous necrosis, and higher erythrocyte sedimentation rate and C-reactive protein levels [<a href="#rid58">58</a>]. Certain autoantibodies are also associated with increased risk for malignancy. (See  <a class="medical medical_review" href="/z/d/html/5162.html" rel="external">"Malignancy in dermatomyositis and polymyositis", section on 'Serum autoantibodies'</a>.) </p><p>The malignancies associated with dermatomyositis include a wide range of tumor types. Ovarian, cervical, breast, uterine, lung, gastric, colorectal, and pancreatic cancers are frequently reported. Associated malignancies are usually detected within three years of diagnosis, and the majority are detected within one year. Muscle disease is more likely to improve with treatment of an underlying cancer than skin disease [<a href="#rid1">1,2</a>]. The risk for malignancy and the diagnostic workup and follow-up for malignancy in patients with dermatomyositis is reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5162.html" rel="external">"Malignancy in dermatomyositis and polymyositis"</a>.)</p><p class="headingAnchor" id="H17"><span class="h3">Erythroderma</span><span class="headingEndMark"> — </span>Erythroderma or exfoliative erythroderma syndrome is defined as a diffuse and generalized erythema of the skin that may involve over 90 percent of the body surface area. Severe pruritus, ectropion, and generalized lymphadenopathy are not uncommon, and superficial desquamation usually ensues. (See  <a class="medical medical_review" href="/z/d/html/13659.html" rel="external">"Erythroderma in adults"</a>.)</p><p>The most common cause of erythroderma is a preexisting skin disease, such as atopic dermatitis or psoriasis [<a href="#rid59">59</a>], followed by drug hypersensitivity reactions. Most cases of erythroderma linked to malignancy are associated with lymphoid malignancies, particularly cutaneous T cell lymphoma. (See  <a class="medical medical_review" href="/z/d/html/5664.html" rel="external">"Psoriasis: Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/2089.html" rel="external">"Drug eruptions"</a> and  <a class="medical medical_review" href="/z/d/html/1674.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides"</a>.)</p><p>Less commonly, acute myeloid leukemia and solid tumors (eg, lung, prostate, thyroid, liver, ovaries, rectum, or skin) are associated with paraneoplastic erythroderma [<a href="#rid60">60</a>]. Paraneoplastic dermatomyositis may also be initially confused with diffuse erythroderma [<a href="#rid61">61</a>]. (See  <a class="medical medical_review" href="/z/d/html/5162.html" rel="external">"Malignancy in dermatomyositis and polymyositis"</a>.)</p><p>The diagnostic workup of an erythrodermic patient should involve a detailed history and physical examination, with special attention to medication history and the history of preexisting skin conditions, systemic disorders, and neoplasia. Erythroderma usually resolves with treatment of the associated malignancy [<a href="#rid2">2</a>]. The evaluation to determine the underlying cause of erythroderma and the management of patients with erythroderma are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/13659.html" rel="external">"Erythroderma in adults", section on 'Determining the underlying cause'</a> and  <a class="medical medical_review" href="/z/d/html/13659.html" rel="external">"Erythroderma in adults", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H3208263"><span class="h3">Erythema gyratum repens</span><span class="headingEndMark"> — </span>Erythema gyratum repens is characterized by concentric rings of rapidly migrating erythematous plaques covering a large percentage of the body surface  (<a class="graphic graphic_picture graphicRef57355 graphicRef58124 graphicRef68112" href="/z/d/graphic/57355.html" rel="external">picture 10A-C</a>). A trailing collarette of scale is evident, and lesions are moderately to severely pruritic. In the vast majority of cases (70 to 80 percent), there is an associated internal malignancy, most often a bronchogenic carcinoma, less commonly esophageal or breast cancer [<a href="#rid62">62-64</a>]. The cutaneous eruption may precede, occur with, or follow the diagnosis of malignancy. Improvement often correlates with successful treatment of the underlying cancer. </p><p>Erythema gyratum repens has also been reported in the setting of benign conditions, such as pulmonary tuberculosis, psoriasis, pityriasis rubra pilaris, and autoimmune disorders [<a href="#rid65">65</a>].</p><p class="headingAnchor" id="H28405609"><span class="h3">Necrolytic migratory erythema</span><span class="headingEndMark"> — </span>Necrolytic migratory erythema (NME) is a transient, weeping eczematous or psoriasiform eruption that occurs in approximately 70 percent of patients with glucagon-secreting pancreatic islet cell tumors (glucagonomas). The eruptions primarily occur around body orifices, in skin flexures, and in acral sites  (<a class="graphic graphic_picture graphicRef76162 graphicRef56367 graphicRef73263" href="/z/d/graphic/76162.html" rel="external">picture 11A-C</a>) [<a href="#rid66">66</a>]. Anemia, weight loss, stomatitis, abdominal pain, diarrhea, and thromboembolic phenomena are additional common features. The diagnosis of NME is indicated by the presence of characteristic clinical features, an elevated serum glucagon level, and radiographic or histologic evidence of a glucagon-secreting pancreatic tumor. (See  <a class="medical medical_review" href="/z/d/html/2611.html" rel="external">"Glucagonoma and the glucagonoma syndrome", section on 'Diagnosis'</a>.)</p><p>Although NME has been described as pathognomonic for glucagonoma, some patients with this condition do not have glucagon-producing tumors. These patients are categorized as having pseudoglucagonoma syndrome [<a href="#rid67">67</a>]. Examples of other disorders that have been associated with NME include celiac disease, cirrhosis of the liver, and inflammatory bowel disease [<a href="#rid68">68</a>]. Various extrapancreatic malignancies, such as hepatocellular, lung, and duodenal cancer, and tumors that secrete insulin or insulin-like growth factor-2 also have been linked to NME.</p><p>Treatment with <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> controls NME effectively, but does not appear to affect the underlying malignancy [<a href="#rid69">69</a>]. Surgical removal of the tumor, when feasible, can result in the resolution of NME [<a href="#rid66">66,70</a>]. (See  <a class="medical medical_review" href="/z/d/html/2611.html" rel="external">"Glucagonoma and the glucagonoma syndrome", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H28407824"><span class="h3">Pancreatic panniculitis</span><span class="headingEndMark"> — </span>Pancreatic panniculitis, a form of lobular panniculitis, is a rare condition in which necrosis of fat within the panniculus and other distant foci occurs in the setting of chronic pancreatitis [<a href="#rid71">71</a>]. Pancreatic panniculitis also has occurred in patients with acinar and islet cell pancreatic cancers [<a href="#rid71">71-76</a>]. The term "lipase hypersecretion syndrome" is used to describe the development of pancreatic panniculitis, inflammation of nearby joints, and eosinophilia in the setting of acinar cell carcinoma, often in association with liver metastasis [<a href="#rid77">77-79</a>]. (See  <a class="medical medical_review" href="/z/d/html/2510.html" rel="external">"Pathology of exocrine pancreatic neoplasms", section on 'Acinar cell carcinoma'</a> and  <a class="medical medical_review" href="/z/d/html/13780.html" rel="external">"Panniculitis: Recognition and diagnosis", section on 'Enzymatic destruction'</a>.)</p><p>In pancreatic panniculitis, tender, erythematous to violaceous, ulcerated nodules can occur anywhere on the body but most commonly occur on the upper and lower extremities. Unlike other panniculitides, pancreatic panniculitis nodules may undergo liquefactive necrosis leading to spontaneous ulceration and brown, viscous drainage [<a href="#rid80">80</a>]. The eruption is attributed to the massive release of lipolytic enzymes into the bloodstream [<a href="#rid71">71,73,76</a>]. Patients are systemically ill with fever and weight loss, and joint manifestations may be prominent. Serum lipase and amylase levels are elevated. In cases associated with a pancreatic neoplasm, the tumor is usually advanced by the time cutaneous lesions appear. Nevertheless, treatment may be beneficial [<a href="#rid76">76</a>]. (See  <a class="medical medical_review" href="/z/d/html/13780.html" rel="external">"Panniculitis: Recognition and diagnosis", section on 'Enzymatic destruction'</a>.)</p><p class="headingAnchor" id="H3208826"><span class="h2">Bullous dermatoses</span><span class="headingEndMark"> — </span>Paraneoplastic pemphigus and mucous membrane pemphigoid with antibodies against laminin 332 are autoimmune blistering disorders with a strong association with malignancy.</p><p class="headingAnchor" id="H21"><span class="h3">Paraneoplastic pemphigus</span><span class="headingEndMark"> — </span>Paraneoplastic pemphigus (also known as paraneoplastic autoimmune multiorgan syndrome or PAMS) is a paraneoplastic disorder associated with lymphoreticular malignancies or lymphoproliferative disorders in 84 percent of cases. Non-Hodgkin lymphoma is the most frequent disorder, followed by chronic lymphocytic leukemia and Castleman disease. Paraneoplastic pemphigus most frequently affects adults aged 45 to 70 years; however, children may present with the condition, especially in the setting of Castleman disease [<a href="#rid81">81</a>]. Thymoma, sarcomas, and Waldenström macroglobulinemia are also associated. (See  <a class="medical medical_review" href="/z/d/html/15305.html" rel="external">"Paraneoplastic pemphigus"</a>.)</p><p>The most consistent clinical feature of paraneoplastic pemphigus is a painful stomatitis  (<a class="graphic graphic_picture graphicRef59594" href="/z/d/graphic/59594.html" rel="external">picture 12</a>). Severe pseudomembranous conjunctivitis may also occur in addition to disease of other mucosal sites. Cutaneous manifestations can include tense bullae or lesions resembling erythema multiforme or lichen planus  (<a class="graphic graphic_picture graphicRef79192" href="/z/d/graphic/79192.html" rel="external">picture 13</a>). Extracutaneous manifestations include ocular complications, muscle weakness, myasthenia gravis, and severe involvement of the airways leading to bronchiolitis obliterans [<a href="#rid82">82,83</a>].</p><p>The diagnosis of paraneoplastic pemphigus is made by clinical and histopathologic findings and results of direct immunofluorescence, indirect immunofluorescence of patient’s serum on murine bladder substrate, and/or enzyme-linked immunosorbent assay (ELISA) for antibodies to envoplakin or periplakin. (See  <a class="medical medical_review" href="/z/d/html/15305.html" rel="external">"Paraneoplastic pemphigus", section on 'Diagnosis'</a>.)</p><p>The diagnosis of malignancy precedes the diagnosis of paraneoplastic pemphigus in approximately two-thirds of patients [<a href="#rid84">84</a>]. In a patient with suspected paraneoplastic pemphigus, but without known malignancy, investigation for an underlying malignancy is indicated.</p><p>In patients with Castleman disease or thymoma, resection of the tumor frequently results in remission of paraneoplastic pemphigus. However, with other malignancies, paraneoplastic pemphigus often progresses independent of the status of the malignancy and may require treatment with immunosuppressive therapies [<a href="#rid85">85</a>]. Paraneoplastic pemphigus is discussed in greater detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/15305.html" rel="external">"Paraneoplastic pemphigus"</a>.)</p><p class="headingAnchor" id="H2292429"><span class="h3">Mucous membrane pemphigoid</span><span class="headingEndMark"> — </span>Mucous membrane pemphigoid (MMP) with antibodies against laminin 332 (previously known as laminin 5 or epiligrin) is an autoimmune blistering condition characterized by severe, painful blisters and erosions on the oral mucosa and skin manifestations consisting of bullae and erosions on an erythematous base. Distinction from other types of MMP is important because of an elevated risk for cancer associated with this subtype [<a href="#rid86">86</a>]. The types of cancer that occur in patients with anti-laminin 332 MMP vary; most are solid tumors. (See  <a class="medical medical_review" href="/z/d/html/16176.html" rel="external">"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid", section on 'Malignancy'</a>.)</p><p>Nearly all patients have mucosal involvement, and possible severe sequelae include gingival destruction, tooth loss, blindness, dysphagia, dysphonia, and airway compromise. The diagnosis of anti-laminin 332 MMP cannot be made clinically, as features are similar to other types of MMP. The detection of antibodies bound to the dermal side of salt-split skin on indirect immunofluorescence is suggestive of this condition. However, confirmatory tests for anti-laminin 332 antibodies are limited to specialized centers and research settings. Patients with this finding should undergo age-appropriate malignancy screening. Immunosuppressive therapy may be effective for improving symptoms; however, the disease course often is progressive. (See  <a class="medical medical_review" href="/z/d/html/16176.html" rel="external">"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid"</a> and  <a class="medical medical_review" href="/z/d/html/83575.html" rel="external">"Management of mucous membrane pemphigoid"</a>.)</p><p class="headingAnchor" id="H28406275"><span class="h2">Hyperpigmentation</span><span class="headingEndMark"> — </span>Widespread hyperpigmentation can be a prominent cutaneous finding in patients with malignancy-associated ectopic Cushing's syndrome or metastatic melanoma. In addition, patients with malignancy-associated acanthosis nigricans may have hyperpigmentation in the affected areas. (See <a class="local">'Acanthosis nigricans'</a> above.)</p><p class="headingAnchor" id="H28405279"><span class="h3">Hyperpigmentation in ectopic Cushing's syndrome</span><span class="headingEndMark"> — </span>Ectopic Cushing's syndrome is the most common hormonally induced paraneoplastic syndrome associated with internal malignancy. The syndrome is characterized by generalized hyperpigmentation (cutaneous and mucosal), muscle wasting, proximal muscle weakness, abnormal fat distribution, peripheral edema, hypokalemic metabolic alkalosis, abnormal glucose tolerance, and hypertension [<a href="#rid87">87</a>]. (See  <a class="medical medical_review" href="/z/d/html/143.html" rel="external">"Epidemiology and clinical manifestations of Cushing syndrome"</a>.)</p><p>Ectopic Cushing's syndrome is caused by hypersecretion of proopiomelanocortin (POMC) from tumors outside of the pituitary gland. POMC is a prohormone of melanocyte-stimulating hormone (MSH) and adrenocorticotropic hormone (ACTH). Both MSH and ACTH are capable of stimulating melanin synthesis, which leads to the development of hyperpigmentation [<a href="#rid88">88</a>]. (See  <a class="medical medical_review" href="/z/d/html/125.html" rel="external">"Causes and pathophysiology of Cushing syndrome"</a>.)</p><p>The most common cause of ectopic Cushing's syndrome is lung carcinoma, specifically the small cell neuroendocrine type. Cushing's syndrome is less frequently associated with carcinoid tumors, thymomas, and pheochromocytomas. (See  <a class="medical medical_review" href="/z/d/html/4628.html" rel="external">"Pathobiology and staging of small cell carcinoma of the lung"</a> and  <a class="medical medical_review" href="/z/d/html/2614.html" rel="external">"Clinical features of carcinoid syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/4619.html" rel="external">"Clinical presentation and management of thymoma and thymic carcinoma"</a>.)</p><p>In Cushing's syndrome, the normal diurnal variation in cortisol production is absent and most patients do not respond normally to the 48-hour <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> suppression test. Surgical removal of the ACTH-producing tumor is the treatment of choice, but in the case of small cell lung cancer, chemotherapy is more often considered. (See  <a class="medical medical_review" href="/z/d/html/156.html" rel="external">"Establishing the cause of Cushing syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/174.html" rel="external">"Overview of the treatment of Cushing syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/4633.html" rel="external">"Extensive-stage small cell lung cancer: Initial management"</a>.)</p><p class="headingAnchor" id="H28405442"><span class="h3">Generalized dermal melanosis</span><span class="headingEndMark"> — </span>Rarely, generalized melanosis with a diffuse slate-gray color to the skin may develop in a patient with extensive metastatic melanoma [<a href="#rid89">89-91</a>]. Since malignant melanocytes are rarely detected in involved areas, pigmentation is thought to be due to dissemination of melanin pigment with uptake by dermal macrophages [<a href="#rid92">92</a>]. </p><p>The pathogenesis of generalized melanosis is not well understood. Pigmentation resulting from aberrant production of melanocyte growth factors is one of multiple theories [<a href="#rid89">89,91,93</a>].</p><p class="headingAnchor" id="H28406635"><span class="h2">Purpura and petechiae</span><span class="headingEndMark"> — </span>Purpura and petechiae are common features of vasculitis and primary (AL) amyloidosis. Both disorders can occur in the setting of an underlying malignancy.</p><p class="headingAnchor" id="H28406699"><span class="h3">Vasculitis</span><span class="headingEndMark"> — </span>Malignancy-associated vasculitis is rare and occurs more often with hematologic malignancies than with solid malignancies [<a href="#rid94">94</a>]. The associated hematologic malignancies are typically lymphoproliferative, or less frequently, myelodysplastic. </p><p>In patients with hematologic malignancies, the most common presentation is a small vessel cutaneous leukocytoclastic vasculitis. Similar to non-malignancy-associated leukocytoclastic vasculitis, malignancy-associated leukocytoclastic vasculitis typically presents with palpable purpura that are preferentially located in dependent areas  (<a class="graphic graphic_picture graphicRef58626 graphicRef70300" href="/z/d/graphic/58626.html" rel="external">picture 14A-B</a>) [<a href="#rid95">95,96</a>]. Solid tumors are associated with various types of vasculitis, including polyarteritis nodosa, immunoglobulin A vasculitis (Henoch-Schönlein purpura), and small-vessel vasculitis [<a href="#rid97">97,98</a>]. (See  <a class="medical medical_review" href="/z/d/html/8245.html" rel="external">"Clinical manifestations and diagnosis of polyarteritis nodosa in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6406.html" rel="external">"IgA vasculitis (Henoch-Schönlein purpura): Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/13769.html" rel="external">"Evaluation of adults with cutaneous lesions of vasculitis", section on 'When to suspect cutaneous vasculitis'</a>.)</p><p>Vasculitis may occur a few years before diagnosis of a malignancy, closer to the time of diagnosis, or following the diagnosis of malignancy [<a href="#rid96">96</a>]. The proportion of patients with vasculitis who harbor an underlying malignancy is not well characterized but appears to be small. Workup for underlying malignancy, therefore, should be guided by associated findings on history, physical examination, or basic laboratory tests. Successful treatment of the underlying malignancy may lead to resolution of vasculitis [<a href="#rid94">94,99</a>]. (See  <a class="medical medical_review" href="/z/d/html/13769.html" rel="external">"Evaluation of adults with cutaneous lesions of vasculitis"</a>.)</p><p class="headingAnchor" id="H28407675"><span class="h3">Amyloidosis</span><span class="headingEndMark"> — </span>Amyloidosis refers to the extracellular tissue deposition of fibrils composed of low molecular weight subunits (5 to 25 kD) of a variety of low molecular weight serum proteins. In primary (AL) amyloidosis, fragments of monoclonal light chains with or without heavy chains are deposited in the kidney and other tissues, including the skin. AL amyloidosis can occur alone or in association with plasma cell dyscrasias such as multiple myeloma, and less frequently, Waldenström macroglobulinemia. In patients with multiple myeloma, the myeloma is typically diagnosed before or concurrently with the amyloidosis diagnosis. Rarely, multiple myeloma develops more than six months after evident amyloidosis. (See  <a class="medical medical_review" href="/z/d/html/6668.html" rel="external">"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis", section on 'Relation to other plasma cell disorders'</a>.)</p><p>The most common mucocutaneous findings in amyloidosis are purpura, petechiae, and ecchymoses following minor trauma ("pinch purpura")  (<a class="graphic graphic_picture graphicRef77887" href="/z/d/graphic/77887.html" rel="external">picture 15</a>). A classic finding is the appearance of periorbital purpura following a Valsalva maneuver or dependent positioning of the head. Macroglossia  (<a class="graphic graphic_picture graphicRef65060" href="/z/d/graphic/65060.html" rel="external">picture 16</a>), waxy papules and plaques, enlarged shoulder pads, bullous lesions, and sclerodermatous changes in the skin may also be seen. </p><p>The diagnosis and management of AL amyloidosis is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6668.html" rel="external">"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis"</a> and  <a class="medical medical_review" href="/z/d/html/6666.html" rel="external">"Treatment and prognosis of immunoglobulin light chain (AL) amyloidosis"</a>.)</p><p class="headingAnchor" id="H28406795"><span class="h2">Scleroderma-like dermatoses</span><span class="headingEndMark"> — </span>Scleromyxedema and scleredema are rare connective tissue disorders that have been associated with paraproteinemias [<a href="#rid100">100,101</a>].</p><p class="headingAnchor" id="H28414818"><span class="h3">Scleromyxedema</span><span class="headingEndMark"> — </span>Scleromyxedema is characterized by waxy yellow-red papules often arranged in a linear fashion. The cutaneous findings occur most commonly on the face, neck, forearms, and hands  (<a class="graphic graphic_picture graphicRef91117 graphicRef91120" href="/z/d/graphic/91117.html" rel="external">picture 17A-B</a>). When the papules coalesce, induration similar to sclerodermatous changes may be noted [<a href="#rid102">102</a>]. Associated findings may include sparse eyebrow, axillary, and pubic hair and leonine facies. Middle-aged adults are most commonly affected. (See  <a class="medical medical_review" href="/z/d/html/89048.html" rel="external">"Scleromyxedema"</a>.)</p><p>Scleromyxedema typically occurs in the presence of paraproteinemia. Scleromyxedema without paraproteinemia is considered an atypical presentation. A monoclonal gammopathy characterized by an IgG lambda paraprotein is commonly detected, but myeloma is rare [<a href="#rid103">103,104</a>]. </p><p>A variety of agents have been used to induce remission of scleromyxedema; however, results are inconsistent. Successful treatment of scleromyxedema does not appear to be dependent upon the resolution of the paraproteinemia. (See  <a class="medical medical_review" href="/z/d/html/89048.html" rel="external">"Scleromyxedema", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H28414868"><span class="h3">Scleredema</span><span class="headingEndMark"> — </span>Scleredema is characterized by firm, stiff indurated skin on the posterior and lateral portion of the neck and the upper back  (<a class="graphic graphic_picture graphicRef90965" href="/z/d/graphic/90965.html" rel="external">picture 18</a>). The stiffness is caused by increased mucin deposition in the skin. Although scleredema most commonly follows a viral upper respiratory infection or the onset of diabetes mellitus, patients with persistent scleredema often have an associated monoclonal gammopathy [<a href="#rid105">105</a>]. Others have reported the development of myeloma in such patients [<a href="#rid106">106,107</a>]. (See  <a class="medical medical_review" href="/z/d/html/89274.html" rel="external">"Scleredema"</a>.)</p><p>Since cutaneous manifestations can precede the monoclonal gammopathy, immunoelectrophoresis should be performed routinely in patients with scleredema, especially if diffuse. It is uncertain whether treatment of the associated underlying disease alters the clinical course of scleredema. (See  <a class="medical medical_review" href="/z/d/html/89274.html" rel="external">"Scleredema", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/89048.html" rel="external">"Scleromyxedema", section on 'Treatment'</a>.) </p><p class="headingAnchor" id="H28406282"><span class="h2">Hair and nail changes</span><span class="headingEndMark"> — </span>Paraneoplastic dermatoses associated with hair or nail disorders include hypertrichosis lanuginosa and hypertrophic osteoarthropathy. Nail changes are also a common finding in Bazex syndrome. (See <a class="local">'Bazex syndrome'</a> above.)</p><p class="headingAnchor" id="H28406336"><span class="h3">Hypertrichosis lanuginosa</span><span class="headingEndMark"> — </span>Hypertrichosis lanuginosa (malignant down) refers to the appearance of fine hair growth, which is predominantly localized to the head and neck but may spread to the torso, arms, and legs  (<a class="graphic graphic_picture graphicRef70105" href="/z/d/graphic/70105.html" rel="external">picture 19</a>) [<a href="#rid108">108-110</a>]. A strong association of this unusual hair growth has been described with adenocarcinomas arising in the large bowel, breast, lung, and kidney [<a href="#rid20">20,108</a>]. </p><p>Hypertrichosis lanuginosa usually presents in patients with advanced or metastatic cancer; rare early and very delayed presentations also have been reported [<a href="#rid111">111,112</a>]. Removal of the malignancy may lead to resolution of the excess hair growth. (See  <a class="medical medical_review" href="/z/d/html/7439.html" rel="external">"Pathophysiology and causes of hirsutism"</a>.)</p><p>In addition, there is a congenital form of hypertrichosis lanuginosa that is not associated with malignancy. Congenital hypertrichosis lanuginosa is present at birth [<a href="#rid113">113</a>].</p><p class="headingAnchor" id="H28406491"><span class="h3">Hypertrophic osteoarthropathy</span><span class="headingEndMark"> — </span>Hypertrophic osteoarthropathy, which is characterized by the development of clubbed fingers, periostitis of long tubular bones, and arthritis, can occur secondary to chronic pulmonary or cardiac conditions producing peripheral hypoxia  (<a class="graphic graphic_picture graphicRef80452 graphicRef61526" href="/z/d/graphic/80452.html" rel="external">picture 20A-B</a> and <a class="graphic graphic_figure graphicRef52839" href="/z/d/graphic/52839.html" rel="external">figure 1</a> and <a class="graphic graphic_diagnosticimage graphicRef57502 graphicRef70330" href="/z/d/graphic/57502.html" rel="external">image 1A-B</a>). There is also an association with lung cancer, primarily non-small cell lung cancer [<a href="#rid114">114,115</a>]. Symptoms may improve with treatment of the associated lung cancer [<a href="#rid115">115,116</a>]. (See  <a class="medical medical_review" href="/z/d/html/5615.html" rel="external">"Malignancy and rheumatic disorders", section on 'Hypertrophic osteoarthropathy'</a>.)</p><p>Hypertrophic osteoarthropathy secondary to pulmonary or cardiac disorders should be distinguished from primary hypertrophic osteoarthropathy, a hereditary disorder that presents with similar features. (See  <a class="medical medical_review" href="/z/d/html/5615.html" rel="external">"Malignancy and rheumatic disorders", section on 'Hypertrophic osteoarthropathy'</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Other paraneoplastic dermatoses</span></p><p class="headingAnchor" id="H24"><span class="h3">Pruritus</span><span class="headingEndMark"> — </span>In patients with generalized pruritus who are not jaundiced, a search for systemic diseases should be initiated to rule out associated disorders such as thyroid disease and hepatic and renal insufficiency [<a href="#rid117">117</a>]. Malignant neoplasms may underlie some cases of generalized, refractory pruritus, most commonly lymphoma (particularly Hodgkin lymphoma), multiple myeloma, leukemia, and carcinoid tumor involving the stomach [<a href="#rid118">118</a>]. In contrast to the usually nonpruritic intermittent cutaneous flushing associated with intestinal carcinoid tumors, the intermittent "histamine" flush associated with atypical gastric carcinoid tumors tends to be pruritic. Occasionally, pruritus presents years before the diagnosis of a malignancy. Malignancy-associated pruritus may improve with treatment of the underlying malignancy [<a href="#rid119">119</a>]. (See  <a class="medical medical_review" href="/z/d/html/16589.html" rel="external">"Pruritus: Etiology and patient evaluation", section on 'Malignancy'</a>.)</p><p>The evaluation of patients with generalized pruritus is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/16589.html" rel="external">"Pruritus: Etiology and patient evaluation", section on 'Generalized pruritus without primary skin lesions'</a>.)</p><p class="headingAnchor" id="H28414907"><span class="h3">Multicentric reticulohistiocytosis</span><span class="headingEndMark"> — </span>Multicentric reticulohistiocytosis (MRH) is a rare multisystem disease consisting of a cutaneous histiocytosis and destructive polyarthritis. MRH is associated with an underlying malignancy in one-quarter of patients. A variety of malignancies have been linked to MRH; breast, hematologic, and gastric cancers are most common [<a href="#rid120">120</a>].</p><p>Flesh-colored to yellow-brown papules and nodules are seen with a predilection for the upper body, and most frequently occur on the face, hands, forearms, and ears. Lesions around the fingernails have a "coral bead" appearance  (<a class="graphic graphic_picture graphicRef77307" href="/z/d/graphic/77307.html" rel="external">picture 21</a>). In addition, xanthelasma has been noted in one-third of patients with MRH. The arthritis of MRH can be rapidly destructive and progress to arthritis mutilans in half of the patients. Other associated symptoms include fever, weight loss, and weakness. Although resolution of MRH following treatment of the underlying cancer has been reported, it is debated whether there is a clear correlation between disease activity in MRH and successful treatment of the associated malignancy [<a href="#rid121">121</a>].</p><p class="headingAnchor" id="H28415002"><span class="h3">Plane xanthomas</span><span class="headingEndMark"> — </span>Plane xanthomas can occur in patients with lipid disorders, but may also herald the presence of monoclonal gammopathy, multiple myeloma, or less frequently, other hematologic malignancies or lymphoproliferative disorders [<a href="#rid122">122</a>]. The term normolipemic plane xanthoma is used to refer to the development of plane xanthomas in patients who lack concomitant hyperlipidemia.</p><p>Plane xanthomas usually present as yellowish to reddish macules, papules, patches, or slightly elevated plaques that have a predilection for the face, neck, upper trunk, and intertriginous areas  (<a class="graphic graphic_picture graphicRef57954" href="/z/d/graphic/57954.html" rel="external">picture 22</a>). In some cases, plane xanthoma precedes the appearance of a hematologic disorder by several years [<a href="#rid122">122</a>]. It is theorized that the myeloma proteins interfere with lipid metabolism, leading to cutaneous deposition. In our experience, plane xanthomas often persist after treatment of the associated malignancy. (See  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H585967048"><span class="h3">Acquired cutis laxa</span><span class="headingEndMark"> — </span>Cutis laxa can be inherited or acquired and results in loose, wrinkled, and redundant skin due to defects in elastic tissue. Internal manifestations may occur and include intestinal diverticula, pulmonary emphysema, hernias, and cardiovascular dilatations. </p><p>Acquired cutis laxa develops later in life and has been attributed to infections, medications, inflammatory dermatoses, and plasma cell dyscrasias [<a href="#rid123">123</a>]. The progression is often cephalocaudal in the generalized, acquired form with the development of "hound dog" facies preceding lax skin of the trunk and extremities. Localized forms have also been described, including acral acquired cutis laxa affecting the fingertips associated with plasma cell dyscrasia. </p><p>Biopsy of the skin will show elastolysis and elastophagocytosis by giant cells. Deposition of myeloma-associated immunoglobulins on elastic fibers of the skin has been demonstrated, likely leading to elastic fiber destruction [<a href="#rid124">124</a>]. </p><p>Patients with adult onset of loose, redundant skin should be biopsied and if decreased elastic fibers are evident, should be evaluated for plasma cell dyscrasia by serum protein electrophoresis and immunofixation, along with assessment for other causes (infection, medication reactions, coexistent or preceding dermatoses). In generalized forms, evaluation for internal manifestations is recommended.</p><p class="headingAnchor" id="H28415396"><span class="h1">NON-PARANEOPLASTIC CUTANEOUS MANIFESTATIONS OF INTERNAL MALIGNANCY</span><span class="headingEndMark"> — </span>Cutaneous disorders that represent tumoral infiltration into the skin are not considered paraneoplastic dermatoses. Examples include cutaneous metastases and leukemia cutis.</p><p class="headingAnchor" id="H28415402"><span class="h2">Cutaneous metastases</span><span class="headingEndMark"> — </span>Occasionally, internal cancers metastasize to the skin through hematogenous or lymphatic spread of tumor cells. Tumor cells from an internal cancer may also appear in the skin as a result of direct tissue invasion or iatrogenic implantation [<a href="#rid125">125</a>]. </p><p>Estimates for the frequency of cutaneous metastasis range from less than 1 percent to 10 percent of patients with internal cancers [<a href="#rid125">125,126</a>]. The clinical manifestations vary widely. Patients may develop papules, plaques, nodules, or ulcers  (<a class="graphic graphic_picture graphicRef99798" href="/z/d/graphic/99798.html" rel="external">picture 23</a>). </p><p>In some cases, cutaneous metastasis is the initial sign that leads to the diagnosis of an internal malignancy [<a href="#rid126">126</a>]. Cutaneous metastases often herald a poor prognosis [<a href="#rid126">126</a>].</p><p class="headingAnchor" id="H28415476"><span class="h2">Leukemia cutis</span><span class="headingEndMark"> — </span>Leukemia cutis describes the cutaneous manifestations that result from the entry of neoplastic leukocytes into the skin. The disorder is more common in patients with acute myeloid leukemia than in patients with chronic myeloproliferative disease [<a href="#rid127">127</a>]. (See  <a class="medical medical_review" href="/z/d/html/4497.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia", section on 'Skin'</a>.)</p><p>The clinical manifestations of leukemia cutis vary. Affected patients typically present with single or multiple red-brown, violaceous, or hemorrhagic papules, nodules, or plaques  (<a class="graphic graphic_picture graphicRef55331" href="/z/d/graphic/55331.html" rel="external">picture 24</a>) [<a href="#rid127">127</a>]. </p><p class="headingAnchor" id="H11694078"><span class="h1">HERITABLE CONDITIONS ASSOCIATED WITH SKIN DISORDERS AND MALIGNANCY</span><span class="headingEndMark"> — </span>Several inherited conditions that predispose to internal malignancy have associated cutaneous manifestations. These include: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cowden syndrome </strong>– Trichilemmomas (adnexal tumors  (<a class="graphic graphic_picture graphicRef60952" href="/z/d/graphic/60952.html" rel="external">picture 25</a>)) with multiple hamartomatous lesions and an increased risk of early-onset breast and thyroid cancer. (See  <a class="medical medical_review" href="/z/d/html/16543.html" rel="external">"PTEN hamartoma tumor syndromes, including Cowden syndrome", section on 'Mucocutaneous'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peutz-Jeghers syndrome </strong>– Multiple hamartomatous polyps in the gastrointestinal tract (with malignant potential) in association with distinctive mucocutaneous pigmentations  (<a class="graphic graphic_picture graphicRef55335" href="/z/d/graphic/55335.html" rel="external">picture 26</a>). (See  <a class="medical medical_review" href="/z/d/html/2533.html" rel="external">"Peutz-Jeghers syndrome: Clinical manifestations, diagnosis, and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Muir-Torre syndrome </strong>– Multiple sebaceous gland and skin tumors, including keratoacanthomas, in conjunction with visceral cancers [<a href="#rid128">128-130</a>]. (See  <a class="medical medical_review" href="/z/d/html/2605.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gardner syndrome </strong>– Desmoid tumors, sebaceous or epidermoid cysts, lipomas, osteomas supernumerary teeth, gastric polyps, juvenile nasopharyngeal angiofibromas, and intestinal adenocarcinomas. (See  <a class="medical medical_review" href="/z/d/html/2598.html" rel="external">"Gardner syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurofibromatosis type 1</strong> – Cutaneous and subcutaneous neurofibromas, café-au-lait macules with optic pathway gliomas, and other tumors involving the nervous system. (See  <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis"</a>.)</p><p></p><p>Examples of other heritable conditions associated with malignancy and prominent cutaneous findings include Birt-Hogg-Dubé syndrome and multiple endocrine neoplasia syndromes. In addition, some patients with a strong family history of melanoma have an increased risk for pancreatic cancer. (See  <a class="medical medical_review" href="/z/d/html/2948.html" rel="external">"Hereditary kidney cancer syndromes", section on 'Birt-Hogg-Dubé syndrome'</a> and  <a class="medical medical_review" href="/z/d/html/2039.html" rel="external">"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/7870.html" rel="external">"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2"</a> and  <a class="medical medical_review" href="/z/d/html/7624.html" rel="external">"Inherited susceptibility to melanoma", section on 'CDKN2A gene'</a> and  <a class="medical medical_review" href="/z/d/html/2939.html" rel="external">"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis", section on 'Tumors'</a>.)</p><p class="headingAnchor" id="H11693911"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview </strong>– A wide variety of cutaneous disorders can occur in the setting of malignancy. Skin conditions that are associated with neoplastic disorders, but do not represent cutaneous infiltration of malignant cells constitute the paraneoplastic dermatoses. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical relevance </strong>– Knowledge of the paraneoplastic dermatoses is of value in the clinical setting. The presence of unexplained cutaneous findings consistent with a paraneoplastic disorder can indicate the need to evaluate a patient for an underlying internal malignancy. (See <a class="local">'Paraneoplastic dermatoses'</a> above.)</p><p></p><p class="bulletIndent1">For some paraneoplastic dermatoses, successful treatment of the underlying malignancy results in resolution of the dermatosis. (See <a class="local">'Paraneoplastic dermatoses'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Thiers BH, Sahn RE, Callen JP. Cutaneous manifestations of internal malignancy. CA Cancer J Clin 2009; 59:73.</a></li><li><a class="nounderline abstract_t">Ehst BD, Minzer-Conzetti K, Swerdlin A, Devere TS. Cutaneous manifestations of internal malignancy. Curr Probl Surg 2010; 47:384.</a></li><li><a class="nounderline abstract_t">Krawczyk M, Mykała-Cieśla J, Kołodziej-Jaskuła A. Acanthosis nigricans as a paraneoplastic syndrome. Case reports and review of literature. Pol Arch Med Wewn 2009; 119:180.</a></li><li><a class="nounderline abstract_t">Kamińska-Winciorek G, Brzezińska-Wcisło L, Lis-Swiety A, Krauze E. Paraneoplastic type of acanthosis nigricans in patient with hepatocellular carcinoma. Adv Med Sci 2007; 52:254.</a></li><li><a class="nounderline abstract_t">Serap D, Ozlem S, Melike Y, et al. Acanthosis nigricans in a patient with lung cancer: a case report. Case Rep Med 2010; 2010.</a></li><li><a class="nounderline abstract_t">Oh CW, Yoon J, Kim CY. Malignant Acanthosis Nigricans Associated with Ovarian Cancer. Case Rep Dermatol 2010; 2:103.</a></li><li><a class="nounderline abstract_t">Longshore SJ, Taylor JS, Kennedy A, Nurko S. Malignant acanthosis nigricans and endometrioid adenocarcinoma of the parametrium: the search for malignancy. J Am Acad Dermatol 2003; 49:541.</a></li><li><a class="nounderline abstract_t">Moscardi JL, Macedo NA, Espasandin JA, Piñeyro MI. Malignant acanthosis nigricans associated with a renal tumor. Int J Dermatol 1993; 32:893.</a></li><li><a class="nounderline abstract_t">Lee HC, Ker KJ, Chong WS. Oral Malignant Acanthosis Nigricans and Tripe Palms Associated With Renal Urothelial Carcinoma. JAMA Dermatol 2015; 151:1381.</a></li><li><a class="nounderline abstract_t">Rigel DS, Jacobs MI. Malignant acanthosis nigricans: a review. J Dermatol Surg Oncol 1980; 6:923.</a></li><li><a class="nounderline abstract_t">Brown J, Winkelmann RK. Acanthosis nigricans: a study of 90 cases. Medicine (Baltimore) 1968; 47:33.</a></li><li><a class="nounderline abstract_t">Yeh JS, Munn SE, Plunkett TA, et al. Coexistence of acanthosis nigricans and the sign of Leser-Trélat in a patient with gastric adenocarcinoma: a case report and literature review. J Am Acad Dermatol 2000; 42:357.</a></li><li><a class="nounderline abstract_t">Heaphy MR Jr, Millns JL, Schroeter AL. The sign of Leser-Trélat in a case of adenocarcinoma of the lung. J Am Acad Dermatol 2000; 43:386.</a></li><li><a class="nounderline abstract_t">Ellis DL, Kafka SP, Chow JC, et al. Melanoma, growth factors, acanthosis nigricans, the sign of Leser-Trélat, and multiple acrochordons. A possible role for alpha-transforming growth factor in cutaneous paraneoplastic syndromes. N Engl J Med 1987; 317:1582.</a></li><li><a class="nounderline abstract_t">Wick MR, Patterson JW. Cutaneous paraneoplastic syndromes. Semin Diagn Pathol 2019; 36:211.</a></li><li><a class="nounderline abstract_t">Schwartz RA. Florid cutaneous papillomatosis. Clin Dermatol 1993; 11:89.</a></li><li><a class="nounderline abstract_t">Singhi MK, Gupta LK, Bansal M, et al. Florid cutaneous papillomatosis with adenocarcinoma of stomach in a 35 year old male. Indian J Dermatol Venereol Leprol 2005; 71:195.</a></li><li><a class="nounderline abstract_t">Brinca A, Cardoso JC, Brites MM, et al. Florid cutaneous papillomatosis and acanthosis nigricans maligna revealing gastric adenocarcinoma. An Bras Dermatol 2011; 86:573.</a></li><li><a class="nounderline abstract_t">Klieb HB, Avon SL, Gilbert J, et al. Florid cutaneous and mucosal papillomatosis: mucocutaneous markers of an underlying gastric malignancy. J Clin Oncol 2013; 31:e218.</a></li><li><a class="nounderline abstract_t">Kurzrock R, Cohen PR. Cutaneous paraneoplastic syndromes in solid tumors. Am J Med 1995; 99:662.</a></li><li><a class="nounderline abstract_t">Schwartz RA. Sign of Leser-Trélat. J Am Acad Dermatol 1996; 35:88.</a></li><li><a class="nounderline abstract_t">Gregory B, Ho VC. Cutaneous manifestations of gastrointestinal disorders. Part II. J Am Acad Dermatol 1992; 26:371.</a></li><li><a class="nounderline abstract_t">Husain Z, Ho JK, Hantash BM. Sign and pseudo-sign of Leser-Trélat: case reports and a review of the literature. J Drugs Dermatol 2013; 12:e79.</a></li><li><a class="nounderline abstract_t">Shah KR, Boland CR, Patel M, et al. Cutaneous manifestations of gastrointestinal disease: part I. J Am Acad Dermatol 2013; 68:189.e1.</a></li><li><a class="nounderline abstract_t">Narala S, Cohen PR. Cutaneous T-cell lymphoma-associated Leser-Trélat sign: report and world literature review. Dermatol Online J 2017; 23.</a></li><li><a class="nounderline abstract_t">Güngör S, Topal I. Images in clinical medicine. Tripe palms. N Engl J Med 2014; 370:558.</a></li><li><a class="nounderline abstract_t">Cohen PR, Grossman ME, Almeida L, Kurzrock R. Tripe palms and malignancy. J Clin Oncol 1989; 7:669.</a></li><li><a class="nounderline abstract_t">Ameen M, Chopra S, Darvay A, et al. Erythema gyratum repens and acquired ichthyosis associated with transitional cell carcinoma of the kidney. Clin Exp Dermatol 2001; 26:510.</a></li><li><a class="nounderline abstract_t">Patel N, Spencer LA, English JC 3rd, Zirwas MJ. Acquired ichthyosis. J Am Acad Dermatol 2006; 55:647.</a></li><li><a class="nounderline abstract_t">Riesco Martínez MC, Muñoz Martín AJ, Zamberk Majlis P, et al. Acquired ichthyosis as a paraneoplastic syndrome in Hodgkin's disease. Clin Transl Oncol 2009; 11:552.</a></li><li><a class="nounderline abstract_t">Rabhi M, Ennibi K, Harket A, et al. Acquired ichthyosis disclosing non-Hodgkin's malignant lymphoma. Intern Med 2007; 46:397.</a></li><li><a class="nounderline abstract_t">Word AP, Cayce R, Pandya AG. Beware of underlying malignancy: acquired ichthyosis. Am J Med 2014; 127:202.</a></li><li><a class="nounderline abstract_t">Spelman LJ, Strutton GM, Robertson IM, Weedon D. Acquired ichthyosis in bone marrow transplant recipients. J Am Acad Dermatol 1996; 35:17.</a></li><li><a class="nounderline abstract_t">Kleyn CE, Lai-Cheong JE, Bell HK. Cutaneous manifestations of internal malignancy: diagnosis and management. Am J Clin Dermatol 2006; 7:71.</a></li><li><a class="nounderline abstract_t">Braun-Falco M. Hereditary palmoplantar keratodermas. J Dtsch Dermatol Ges 2009; 7:971.</a></li><li><a class="nounderline abstract_t">Itin PH, Lautenschlager S. Palmoplantar keratoderma and associated syndromes. Semin Dermatol 1995; 14:152.</a></li><li><a class="nounderline abstract_t">Kim ST, Jeon YS, Sim HJ, et al. Clinicopathologic features and T-cell receptor gene rearrangement findings of mycosis fungoides palmaris et plantaris. J Am Acad Dermatol 2006; 54:466.</a></li><li><a class="nounderline abstract_t">Itin PH, Fistarol SK. Palmoplantar keratodermas. Clin Dermatol 2005; 23:15.</a></li><li><a class="nounderline abstract_t">Richard M, Giroux JM. Acrokeratosis paraneoplastica (Bazex' syndrome). J Am Acad Dermatol 1987; 16:178.</a></li><li><a class="nounderline abstract_t">Lucker GP, Steijlen PM. Acrokeratosis paraneoplastica (Bazex syndrome) occurring with acquired ichthyosis in Hodgkin's disease. Br J Dermatol 1995; 133:322.</a></li><li><a class="nounderline abstract_t">Bolognia JL, Brewer YP, Cooper DL. Bazex syndrome (acrokeratosis paraneoplastica). An analytic review. Medicine (Baltimore) 1991; 70:269.</a></li><li><a class="nounderline abstract_t">Sator PG, Breier F, Gschnait F. Acrokeratosis paraneoplastica (Bazex's syndrome): association with liposarcoma. J Am Acad Dermatol 2006; 55:1103.</a></li><li><a class="nounderline abstract_t">Taher M, Grewal P, Gunn B, et al. Acrokeratosis paraneoplastica (Bazex syndrome) presenting in a patient with metastatic breast carcinoma: possible etiologic role of zinc. J Cutan Med Surg 2007; 11:78.</a></li><li><a class="nounderline abstract_t">Fleming JD, Stefanato CM, Attard NR. Bazex syndrome (acrokeratosis paraneoplastica). Clin Exp Dermatol 2014; 39:955.</a></li><li><a class="nounderline abstract_t">Räßler F, Goetze S, Elsner P. Acrokeratosis paraneoplastica (Bazex syndrome) - a systematic review on risk factors, diagnosis, prognosis and management. J Eur Acad Dermatol Venereol 2017; 31:1119.</a></li><li><a class="nounderline abstract_t">Bolognia JL. Bazex syndrome: acrokeratosis paraneoplastica. Semin Dermatol 1995; 14:84.</a></li><li><a class="nounderline abstract_t">Crucitti A, Feliciani C, Grossi U, et al. Paraneoplastic acrokeratosis (bazex syndrome) in lung cancer. J Clin Oncol 2009; 27:e266.</a></li><li><a class="nounderline abstract_t">Fasanmade A, Farrell K, Perkins CS. Bazex syndrome (acrokeratosis paraneoplastica): persistence of cutaneous lesions after successful treatment of an associated oropharyngeal neoplasm. Br J Oral Maxillofac Surg 2009; 47:138.</a></li><li><a class="nounderline abstract_t">Vaynshtok PM, Tian F, Kaffenberger BH. Acitretin amelioration of Acrokeratosis Paraneoplastica (Bazex Syndrome) in cases of incurable squamous cell carcinoma of the hypopharynx. Dermatol Online J 2016; 22.</a></li><li><a class="nounderline abstract_t">Conde-Montero E, Baniandrés-Rodríguez O, Horcajada-Reales C, et al. Paraneoplastic acrokeratosis (Bazex syndrome): unusual association with in situ follicular lymphoma and response to acitretin. Cutis 2017; 100:E3.</a></li><li><a class="nounderline abstract_t">Esteve E, Serpier H, Cambie MP, et al. [Bazex paraneoplastic acrokeratosis. Treatment with acitretin]. Ann Dermatol Venereol 1995; 122:26.</a></li><li><a class="nounderline abstract_t">Cohen PR, Kurzrock R. Sweet's syndrome revisited: a review of disease concepts. Int J Dermatol 2003; 42:761.</a></li><li><a class="nounderline abstract_t">Cohen PR. Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis 2007; 2:34.</a></li><li><a class="nounderline abstract_t">Cohen PR, Kurzrock R. Sweet's syndrome and cancer. Clin Dermatol 1993; 11:149.</a></li><li><a class="nounderline abstract_t">Haber R, Feghali J, El Gemayel M. Risk of malignancy in histiocytoid Sweet syndrome: A systematic review and reappraisal. J Am Acad Dermatol 2020; 83:661.</a></li><li><a class="nounderline abstract_t">Jung EH, Park JH, Hwan Kim K, et al. Characteristics of Sweet syndrome in patients with or without malignancy. Ann Hematol 2022; 101:1499.</a></li><li><a class="nounderline abstract_t">Nelson CA, Stephen S, Ashchyan HJ, et al. Neutrophilic dermatoses: Pathogenesis, Sweet syndrome, neutrophilic eccrine hidradenitis, and Behçet disease. J Am Acad Dermatol 2018; 79:987.</a></li><li><a class="nounderline abstract_t">Lu X, Yang H, Shu X, et al. Factors predicting malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis. PLoS One 2014; 9:e94128.</a></li><li><a class="nounderline abstract_t">Nicolis GD, Helwig EB. Exfoliative dermatitis. A clinicopathologic study of 135 cases. Arch Dermatol 1973; 108:788.</a></li><li><a class="nounderline abstract_t">King LE Jr, Dufresne RG Jr, Lovett GL, Rosin MA. Erythroderma: review of 82 cases. South Med J 1986; 79:1210.</a></li><li><a class="nounderline abstract_t">Nousari HC, Kimyai-Asadi A, Spegman DJ. Paraneoplastic dermatomyositis presenting as erythroderma. J Am Acad Dermatol 1998; 39:653.</a></li><li><a class="nounderline abstract_t">Appell ML, Ward WQ, Tyring SK. Erythema gyratum repens. A cutaneous marker of malignancy. Cancer 1988; 62:548.</a></li><li><a class="nounderline abstract_t">Eubanks LE, McBurney E, Reed R. Erythema gyratum repens. Am J Med Sci 2001; 321:302.</a></li><li><a class="nounderline abstract_t">Rongioletti F, Fausti V, Parodi A. Erythema gyratum repens is not an obligate paraneoplastic disease: a systematic review of the literature and personal experience. J Eur Acad Dermatol Venereol 2014; 28:112.</a></li><li><a class="nounderline abstract_t">Demonchy E, Lacour JP, Ortonne JP, Passeron T. Erythema gyratum repens, not always a bad omen for patients. J Eur Acad Dermatol Venereol 2010; 24:738.</a></li><li><a class="nounderline abstract_t">Lobo I, Carvalho A, Amaral C, et al. Glucagonoma syndrome and necrolytic migratory erythema. Int J Dermatol 2010; 49:24.</a></li><li><a class="nounderline abstract_t">Marinkovich MP, Botella R, Datloff J, Sangueza OP. Necrolytic migratory erythema without glucagonoma in patients with liver disease. J Am Acad Dermatol 1995; 32:604.</a></li><li><a class="nounderline abstract_t">Tierney EP, Badger J. Etiology and pathogenesis of necrolytic migratory erythema: review of the literature. MedGenMed 2004; 6:4.</a></li><li><a class="nounderline abstract_t">Chastain MA. The glucagonoma syndrome: a review of its features and discussion of new perspectives. Am J Med Sci 2001; 321:306.</a></li><li><a class="nounderline abstract_t">Remes-Troche JM, García-de-Acevedo B, Zuñiga-Varga J, et al. Necrolytic migratory erythema: a cutaneous clue to glucagonoma syndrome. J Eur Acad Dermatol Venereol 2004; 18:591.</a></li><li><a class="nounderline abstract_t">García-Romero D, Vanaclocha F. Pancreatic panniculitis. Dermatol Clin 2008; 26:465.</a></li><li><a class="nounderline abstract_t">Bennett RG, Petrozzi JW. Nodular subcutaneous fat necrosis. A manifestation of silent pancreatitis. Arch Dermatol 1975; 111:896.</a></li><li><a class="nounderline abstract_t">Heykarts B, Anseeuw M, Degreef H. Panniculitis caused by acinous pancreatic carcinoma. Dermatology 1999; 198:182.</a></li><li><a class="nounderline abstract_t">Dahl PR, Su WP, Cullimore KC, Dicken CH. Pancreatic panniculitis. J Am Acad Dermatol 1995; 33:413.</a></li><li><a class="nounderline abstract_t">Lewis CT 3rd, Tschen JA, Klima M. Subcutaneous fat necrosis associated with pancreatic islet cell carcinoma. Am J Dermatopathol 1991; 13:52.</a></li><li><a class="nounderline abstract_t">van Klaveren RJ, de Mulder PH, Boerbooms AM, et al. Pancreatic carcinoma with polyarthritis, fat necrosis, and high serum lipase and trypsin activity. Gut 1990; 31:953.</a></li><li><a class="nounderline abstract_t">Taskin OC, Adsay V. Lipase hypersecretion syndrome: A distinct form of paraneoplastic syndrome specific to pancreatic acinar carcinomas. Semin Diagn Pathol 2019; 36:240.</a></li><li><a class="nounderline abstract_t">Sofela J, Hunt WTN, Chaytor R, et al. A rare case of lipase hypersecretion syndrome. Clin Exp Dermatol 2022; 47:635.</a></li><li><a class="nounderline abstract_t">Nizam W, Shah AA, Rajack F, et al. Lipase hypersecretion syndrome: A rare cutaneous manifestation of advanced pancreatic acinar cell carcinoma. Clin Case Rep 2020; 8:905.</a></li><li><a class="nounderline abstract_t">Rongioletti F, Caputo V. Pancreatic panniculitis. G Ital Dermatol Venereol 2013; 148:419.</a></li><li><a class="nounderline abstract_t">Czernik A, Camilleri M, Pittelkow MR, Grando SA. Paraneoplastic autoimmune multiorgan syndrome: 20 years after. Int J Dermatol 2011; 50:905.</a></li><li><a class="nounderline abstract_t">Nousari HC, Deterding R, Wojtczack H, et al. The mechanism of respiratory failure in paraneoplastic pemphigus. N Engl J Med 1999; 340:1406.</a></li><li><a class="nounderline abstract_t">Wang R, Li J, Wang M, et al. Prevalence of myasthenia gravis and associated autoantibodies in paraneoplastic pemphigus and their correlations with symptoms and prognosis. Br J Dermatol 2015; 172:968.</a></li><li><a class="nounderline abstract_t">Sehgal VN, Srivastava G. Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome. Int J Dermatol 2009; 48:162.</a></li><li><a class="nounderline abstract_t">Anhalt GJ. Paraneoplastic pemphigus. J Investig Dermatol Symp Proc 2004; 9:29.</a></li><li><a class="nounderline abstract_t">Egan CA, Lazarova Z, Darling TN, et al. Anti-epiligrin cicatricial pemphigoid and relative risk for cancer. Lancet 2001; 357:1850.</a></li><li><a class="nounderline abstract_t">Pivonello R, De Martino MC, De Leo M, et al. Cushing's Syndrome. Endocrinol Metab Clin North Am 2008; 37:135.</a></li><li><a class="nounderline abstract_t">Wakamatsu K, Graham A, Cook D, Thody AJ. Characterisation of ACTH peptides in human skin and their activation of the melanocortin-1 receptor. Pigment Cell Res 1997; 10:288.</a></li><li><a class="nounderline abstract_t">Böhm M, Schiller M, Nashan D, et al. Diffuse melanosis arising from metastatic melanoma: pathogenetic function of elevated melanocyte peptide growth factors. J Am Acad Dermatol 2001; 44:747.</a></li><li><a class="nounderline abstract_t">Murray C, D'Intino Y, MacCormick R, et al. Melanosis in association with metastatic malignant melanoma: report of a case and a unifying concept of pathogenesis. Am J Dermatopathol 1999; 21:28.</a></li><li><a class="nounderline abstract_t">Perez A, Turajlic S, Szyszko T, et al. Generalized melanosis and melanuria in a patient with metastatic melanoma. Clin Exp Dermatol 2010; 35:e37.</a></li><li><a class="nounderline abstract_t">Spremulli EN, Bogaars HA, Dexter DL, et al. Nude mouse model of the melanosis syndrome. J Natl Cancer Inst 1983; 71:933.</a></li><li><a class="nounderline abstract_t">Steiner A, Rappersberger K, Groh V, Pehamberger H. Diffuse melanosis in metastatic malignant melanoma. J Am Acad Dermatol 1991; 24:625.</a></li><li><a class="nounderline abstract_t">Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum 2007; 57:1473.</a></li><li><a class="nounderline abstract_t">Wooten MD, Jasin HE. Vasculitis and lymphoproliferative diseases. Semin Arthritis Rheum 1996; 26:564.</a></li><li><a class="nounderline abstract_t">El Tal AK, Tannous Z. Cutaneous vascular disorders associated with internal malignancy. Dermatol Clin 2008; 26:45.</a></li><li><a class="nounderline abstract_t">Podjasek JO, Wetter DA, Pittelkow MR, Wada DA. Cutaneous small-vessel vasculitis associated with solid organ malignancies: the Mayo Clinic experience, 1996 to 2009. J Am Acad Dermatol 2012; 66:e55.</a></li><li><a class="nounderline abstract_t">Kurzrock R, Cohen PR, Markowitz A. Clinical manifestations of vasculitis in patients with solid tumors. A case report and review of the literature. Arch Intern Med 1994; 154:334.</a></li><li><a class="nounderline abstract_t">Solans-Laqué R, Bosch-Gil JA, Pérez-Bocanegra C, et al. Paraneoplastic vasculitis in patients with solid tumors: report of 15 cases. J Rheumatol 2008; 35:294.</a></li><li><a class="nounderline abstract_t">Beers WH, Ince A, Moore TL. Scleredema adultorum of Buschke: a case report and review of the literature. Semin Arthritis Rheum 2006; 35:355.</a></li><li><a class="nounderline abstract_t">Cokonis Georgakis CD, Falasca G, Georgakis A, Heymann WR. Scleromyxedema. Clin Dermatol 2006; 24:493.</a></li><li><a class="nounderline abstract_t">Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol 2001; 44:273.</a></li><li><a class="nounderline abstract_t">Kitamura W, Matsuoka Y, Miyagawa S, Sakamoto K. Immunochemical analysis of the monoclonal paraprotein in scleromyxedema. J Invest Dermatol 1978; 70:305.</a></li><li><a class="nounderline abstract_t">Gabriel SE, Perry HO, Oleson GB, Bowles CA. Scleromyxedema: a scleroderma-like disorder with systemic manifestations. Medicine (Baltimore) 1988; 67:58.</a></li><li><a class="nounderline abstract_t">Kövary PM, Vakilzadeh F, Macher E, et al. Monoclonal gammopathy in scleredema. Observations in three cases. Arch Dermatol 1981; 117:536.</a></li><li><a class="nounderline abstract_t">Pujol JA, Bueno M, Fuertes MA, et al. Improvement of scleredema associated with IgA multiple myeloma after chemotherapy. Clin Exp Dermatol 1995; 20:149.</a></li><li><a class="nounderline abstract_t">Hodak E, Tamir R, David M, et al. Scleredema adultorum associated with IgG-kappa multiple myeloma--a case report and review of the literature. Clin Exp Dermatol 1988; 13:271.</a></li><li><a class="nounderline abstract_t">Vulink AJ, ten Bokkel Huinink D. Acquired hypertrichosis lanuginosa: a rare cutaneous paraneoplastic syndrome. J Clin Oncol 2007; 25:1625.</a></li><li><a class="nounderline abstract_t">Slee PH, van der Waal RI, Schagen van Leeuwen JH, et al. Paraneoplastic hypertrichosis lanuginosa acquisita: uncommon or overlooked? Br J Dermatol 2007; 157:1087.</a></li><li><a class="nounderline abstract_t">Russell P, Floridis J. Hypertrichosis lanuginosa acquisita: a rare dermatological disorder. Lancet 2016; 387:2035.</a></li><li><a class="nounderline abstract_t">Worsnop F, Campalani E. Paraneoplastic hypertrichosis lanuginosa acquisita: a delayed presentation in quiescent chronic lymphocytic leukaemia. Clin Exp Dermatol 2014; 39:669.</a></li><li><a class="nounderline abstract_t">Pérez-Losada E, Pujol RM, Domingo P, et al. Hypertrichosis lanuginosa acquisita preceding extraskeletal Ewing's sarcoma. Clin Exp Dermatol 2001; 26:182.</a></li><li><a class="nounderline abstract_t">Mendiratta V, Harjai B, Gupta T. Hypertrichosis lanuginosa congenita. Pediatr Dermatol 2008; 25:483.</a></li><li><a class="nounderline abstract_t">Sridhar KS, Lobo CF, Altman RD. Digital clubbing and lung cancer. Chest 1998; 114:1535.</a></li><li><a class="nounderline abstract_t">Ito T, Goto K, Yoh K, et al. Hypertrophic pulmonary osteoarthropathy as a paraneoplastic manifestation of lung cancer. J Thorac Oncol 2010; 5:976.</a></li><li><a class="nounderline abstract_t">Qian X, Qin J. Hypertrophic pulmonary osteoarthropathy with primary lung cancer. Oncol Lett 2014; 7:2079.</a></li><li><a class="nounderline abstract_t">Gilchrest BA. Pruritus: pathogenesis, therapy, and significance in systemic disease states. Arch Intern Med 1982; 142:101.</a></li><li><a class="nounderline abstract_t">Paul R, Paul R, Jansen CT. Itch and malignancy prognosis in generalized pruritus: a 6-year follow-up of 125 patients. J Am Acad Dermatol 1987; 16:1179.</a></li><li><a class="nounderline abstract_t">Yosipovitch G, Bernhard JD. Clinical practice. Chronic pruritus. N Engl J Med 2013; 368:1625.</a></li><li><a class="nounderline abstract_t">Snow JL, Muller SA. Malignancy-associated multicentric reticulohistiocytosis: a clinical, histological and immunophenotypic study. Br J Dermatol 1995; 133:71.</a></li><li><a class="nounderline abstract_t">Islam AD, Naguwa SM, Cheema GS, et al. Multicentric reticulohistiocytosis: a rare yet challenging disease. Clin Rev Allergy Immunol 2013; 45:281.</a></li><li><a class="nounderline abstract_t">Rosmaninho A, Fernandes I, Guimas A, et al. Diffuse plane xanthomatosis associated with monoclonal gammopathy. An Bras Dermatol 2011; 86:S50.</a></li><li><a class="nounderline abstract_t">New HD, Callen JP. Generalized acquired cutis laxa associated with multiple myeloma with biphenotypic IgG-λ and IgA-κ gammopathy following treatment of a nodal plasmacytoma. Arch Dermatol 2011; 147:323.</a></li><li><a class="nounderline abstract_t">O'Malley JT, D'Agati VD, Sherman WH, Grossman ME. Acquired cutis laxa associated with heavy chain deposition disease involving dermal elastic fibers. JAMA Dermatol 2014; 150:1192.</a></li><li><a class="nounderline abstract_t">Hu SC, Chen GS, Wu CS, et al. Rates of cutaneous metastases from different internal malignancies: experience from a Taiwanese medical center. J Am Acad Dermatol 2009; 60:379.</a></li><li><a class="nounderline abstract_t">Alcaraz I, Cerroni L, Rütten A, et al. Cutaneous metastases from internal malignancies: a clinicopathologic and immunohistochemical review. Am J Dermatopathol 2012; 34:347.</a></li><li><a class="nounderline abstract_t">Cho-Vega JH, Medeiros LJ, Prieto VG, Vega F. Leukemia cutis. Am J Clin Pathol 2008; 129:130.</a></li><li><a class="nounderline abstract_t">Cimen S, Aslan G, Lebe B, et al. Penile keratoacanthoma associated with urothelial carcinoma of the bladder in Muir-Torre syndrome. Urol Oncol 2007; 25:326.</a></li><li><a class="nounderline abstract_t">Ponti G, Ponz de Leon M. Muir-Torre syndrome. Lancet Oncol 2005; 6:980.</a></li><li><a class="nounderline abstract_t">Dores GM, Curtis RE, Toro JR, et al. Incidence of cutaneous sebaceous carcinoma and risk of associated neoplasms: insight into Muir-Torre syndrome. Cancer 2008; 113:3372.</a></li></ol></div><div id="topicVersionRevision">Topic 7606 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19258446" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cutaneous manifestations of internal malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20363406" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cutaneous manifestations of internal malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19514649" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Acanthosis nigricans as a paraneoplastic syndrome. Case reports and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18217428" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Paraneoplastic type of acanthosis nigricans in patient with hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20811563" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Acanthosis nigricans in a patient with lung cancer: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20689633" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Malignant Acanthosis Nigricans Associated with Ovarian Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12963928" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Malignant acanthosis nigricans and endometrioid adenocarcinoma of the parametrium: the search for malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8125695" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Malignant acanthosis nigricans associated with a renal tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26309230" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Oral Malignant Acanthosis Nigricans and Tripe Palms Associated With Renal Urothelial Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6257767" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Malignant acanthosis nigricans: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4868603" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Acanthosis nigricans: a study of 90 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10640933" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Coexistence of acanthosis nigricans and the sign of Leser-Trélat in a patient with gastric adenocarcinoma: a case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10901731" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The sign of Leser-Trélat in a case of adenocarcinoma of the lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2825016" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Melanoma, growth factors, acanthosis nigricans, the sign of Leser-Trélat, and multiple acrochordons. A possible role for alpha-transforming growth factor in cutaneous paraneoplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30736994" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cutaneous paraneoplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8339205" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Florid cutaneous papillomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16394412" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Florid cutaneous papillomatosis with adenocarcinoma of stomach in a 35 year old male.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21738980" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Florid cutaneous papillomatosis and acanthosis nigricans maligna revealing gastric adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23530104" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Florid cutaneous and mucosal papillomatosis: mucocutaneous markers of an underlying gastric malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7503090" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cutaneous paraneoplastic syndromes in solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8682971" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Sign of Leser-Trélat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1307219" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cutaneous manifestations of gastrointestinal disorders. Part II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23652964" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Sign and pseudo-sign of Leser-Trélat: case reports and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23317980" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Cutaneous manifestations of gastrointestinal disease: part I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28329468" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cutaneous T-cell lymphoma-associated Leser-Trélat sign: report and world literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24499214" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Images in clinical medicine. Tripe palms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2651581" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Tripe palms and malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11678878" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Erythema gyratum repens and acquired ichthyosis associated with transitional cell carcinoma of the kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17010746" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Acquired ichthyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19661032" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Acquired ichthyosis as a paraneoplastic syndrome in Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17409605" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Acquired ichthyosis disclosing non-Hodgkin's malignant lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24355352" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Beware of underlying malignancy: acquired ichthyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8682957" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Acquired ichthyosis in bone marrow transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16605288" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Cutaneous manifestations of internal malignancy: diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19341430" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Hereditary palmoplantar keratodermas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7640196" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Palmoplantar keratoderma and associated syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16488298" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Clinicopathologic features and T-cell receptor gene rearrangement findings of mycosis fungoides palmaris et plantaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15708285" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Palmoplantar keratodermas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3819049" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Acrokeratosis paraneoplastica (Bazex' syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7547410" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Acrokeratosis paraneoplastica (Bazex syndrome) occurring with acquired ichthyosis in Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2067411" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Bazex syndrome (acrokeratosis paraneoplastica). An analytic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17097409" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Acrokeratosis paraneoplastica (Bazex's syndrome): association with liposarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17374318" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Acrokeratosis paraneoplastica (Bazex syndrome) presenting in a patient with metastatic breast carcinoma: possible etiologic role of zinc.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25065696" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Bazex syndrome (acrokeratosis paraneoplastica).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28273374" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Acrokeratosis paraneoplastica (Bazex syndrome) - a systematic review on risk factors, diagnosis, prognosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7640201" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Bazex syndrome: acrokeratosis paraneoplastica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19826120" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Paraneoplastic acrokeratosis (bazex syndrome) in lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18775590" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Bazex syndrome (acrokeratosis paraneoplastica): persistence of cutaneous lesions after successful treatment of an associated oropharyngeal neoplasm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28329620" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Acitretin amelioration of Acrokeratosis Paraneoplastica (Bazex Syndrome) in cases of incurable squamous cell carcinoma of the hypopharynx.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28961299" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Paraneoplastic acrokeratosis (Bazex syndrome): unusual association with in situ follicular lymphoma and response to acitretin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7668778" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : [Bazex paraneoplastic acrokeratosis. Treatment with acitretin].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14521689" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Sweet's syndrome revisited: a review of disease concepts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17655751" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8339190" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Sweet's syndrome and cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32092374" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Risk of malignancy in histiocytoid Sweet syndrome: A systematic review and reappraisal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35482090" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Characteristics of Sweet syndrome in patients with or without malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29653210" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Neutrophilic dermatoses: Pathogenesis, Sweet syndrome, neutrophilic eccrine hidradenitis, and Behçet disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24713868" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Factors predicting malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4271796" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Exfoliative dermatitis. A clinicopathologic study of 135 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2945258" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Erythroderma: review of 82 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9777780" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Paraneoplastic dermatomyositis presenting as erythroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3390794" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Erythema gyratum repens. A cutaneous marker of malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11370793" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Erythema gyratum repens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22830929" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Erythema gyratum repens is not an obligate paraneoplastic disease: a systematic review of the literature and personal experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19807824" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Erythema gyratum repens, not always a bad omen for patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20465606" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Glucagonoma syndrome and necrolytic migratory erythema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7896950" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Necrolytic migratory erythema without glucagonoma in patients with liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15520626" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Etiology and pathogenesis of necrolytic migratory erythema: review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11370794" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The glucagonoma syndrome: a review of its features and discussion of new perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15324403" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Necrolytic migratory erythema: a cutaneous clue to glucagonoma syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18793978" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Pancreatic panniculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1147633" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Nodular subcutaneous fat necrosis. A manifestation of silent pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10325476" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Panniculitis caused by acinous pancreatic carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7657863" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Pancreatic panniculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1848412" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Subcutaneous fat necrosis associated with pancreatic islet cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2387523" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Pancreatic carcinoma with polyarthritis, fat necrosis, and high serum lipase and trypsin activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31300257" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Lipase hypersecretion syndrome: A distinct form of paraneoplastic syndrome specific to pancreatic acinar carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34890070" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : A rare case of lipase hypersecretion syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32477543" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Lipase hypersecretion syndrome: A rare cutaneous manifestation of advanced pancreatic acinar cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23900163" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Pancreatic panniculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21781058" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Paraneoplastic autoimmune multiorgan syndrome: 20 years after.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10228191" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The mechanism of respiratory failure in paraneoplastic pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25388377" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Prevalence of myasthenia gravis and associated autoantibodies in paraneoplastic pemphigus and their correlations with symptoms and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19200194" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14870982" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Paraneoplastic pemphigus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11410196" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Anti-epiligrin cicatricial pemphigoid and relative risk for cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18226734" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Cushing's Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9359624" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Characterisation of ACTH peptides in human skin and their activation of the melanocortin-1 receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11312419" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Diffuse melanosis arising from metastatic melanoma: pathogenetic function of elevated melanocyte peptide growth factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10027522" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Melanosis in association with metastatic malignant melanoma: report of a case and a unifying concept of pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20500171" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Generalized melanosis and melanuria in a patient with metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6580495" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Nude mouse model of the melanosis syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2033142" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Diffuse melanosis in metastatic malignant melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18050165" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Vasculitides associated with malignancies: analysis of sixty patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8916300" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Vasculitis and lymphoproliferative diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18023770" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Cutaneous vascular disorders associated with internal malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21093106" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Cutaneous small-vessel vasculitis associated with solid organ malignancies: the Mayo Clinic experience, 1996 to 2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8297201" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Clinical manifestations of vasculitis in patients with solid tumors. A case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18085729" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Paraneoplastic vasculitis in patients with solid tumors: report of 15 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16765712" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Scleredema adultorum of Buschke: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17113967" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Scleromyxedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11174386" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/349088" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Immunochemical analysis of the monoclonal paraprotein in scleromyxedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3336281" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Scleromyxedema: a scleroderma-like disorder with systemic manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6794460" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Monoclonal gammopathy in scleredema. Observations in three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8565252" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Improvement of scleredema associated with IgA multiple myeloma after chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3149919" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Scleredema adultorum associated with IgG-kappa multiple myeloma--a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17443005" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Acquired hypertrichosis lanuginosa: a rare cutaneous paraneoplastic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17941940" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Paraneoplastic hypertrichosis lanuginosa acquisita: uncommon or overlooked?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26364545" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Hypertrichosis lanuginosa acquisita: a rare dermatological disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24712899" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Paraneoplastic hypertrichosis lanuginosa acquisita: a delayed presentation in quiescent chronic lymphocytic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11298112" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Hypertrichosis lanuginosa acquisita preceding extraskeletal Ewing's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18789097" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Hypertrichosis lanuginosa congenita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9872183" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Digital clubbing and lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20453688" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Hypertrophic pulmonary osteoarthropathy as a paraneoplastic manifestation of lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24932292" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Hypertrophic pulmonary osteoarthropathy with primary lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7032441" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Pruritus: pathogenesis, therapy, and significance in systemic disease states.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3597859" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Itch and malignancy prognosis in generalized pruritus: a 6-year follow-up of 125 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23614588" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Clinical practice. Chronic pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7669644" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Malignancy-associated multicentric reticulohistiocytosis: a clinical, histological and immunophenotypic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23417597" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Multicentric reticulohistiocytosis: a rare yet challenging disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22068770" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Diffuse plane xanthomatosis associated with monoclonal gammopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21422340" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Generalized acquired cutis laxa associated with multiple myeloma with biphenotypic IgG-λand IgA-κgammopathy following treatment of a nodal plasmacytoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25133950" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Acquired cutis laxa associated with heavy chain deposition disease involving dermal elastic fibers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19056145" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Rates of cutaneous metastases from different internal malignancies: experience from a Taiwanese medical center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22617133" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Cutaneous metastases from internal malignancies: a clinicopathologic and immunohistochemical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18089498" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Leukemia cutis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17628300" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Penile keratoacanthoma associated with urothelial carcinoma of the bladder in Muir-Torre syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16321766" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Muir-Torre syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18932259" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Incidence of cutaneous sebaceous carcinoma and risk of associated neoplasms: insight into Muir-Torre syndrome.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
